ClinicalTrials.gg
CompletedNCT01749150Updated Nov 2, 2016

A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis

A Phase 2 interventional study of danoprevir + ritonavir and danoprevir + ritonavir in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing danoprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. danoprevir · Hepatitis C, Chronic.

Enrollment
7th of 10
61 · median 79
Started
2013
the only one that year
Phase 2
7 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
7 of 10
Hoffmann-La Roche

Among the 10 studies testing danoprevir in Hepatitis C, Chronic, this one is the 7th largest by enrollment, is the only one that started in 2013, is one of 7 in phase 2, and was the 7th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 10 studies testing danoprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About danoprevir

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing danoprevir in Hepatitis C, Chronic as a file.
02

Study summary

This Phase II, open-label, parallel-arm study will evaluate the safety, tolerability, pharmacokinetics and antiviral activity of ritonavir-boosted danoprevir in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) in treatment-naïve patients of Asian origin with chronic hepatitis C genotype 1. Patients will receive danoprevir 125 mg plus ritonavir 100 mg as fixed dose tablet orally twice daily in combination with weekly Pegasys 180 mcg subcutaneously and Copegus 1000-1200 mg orally daily in divided doses. Treatment duration is 12 weeks in patients without cirrhosis and 24 weeks in patients with compensated cirrhosis.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients of East Asian or Southeast Asian origin, >/= 18 years of age
  • Presence of chronic genotype 1 infection
  • Treatment-naïve

Exclusion criteria

Exclusion Criteria:

  • History or presence of decompensated liver disease
  • Presence or history of non- chronic liver disease
  • Positive for or infection
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    with cirrhosis

    Drug: danoprevir + ritonavir · Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin [Copegus]

  • Experimental
    without cirrhosis

    Drug: danoprevir + ritonavir · Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin [Copegus]

Interventions

06

What researchers measure

Primary outcomes

  1. Safety: Incidence of adverse events

    Time frame: approximately 1.5 years

  2. Pharmacokinetics: Area under the concentration-time curve (AUC) for danoprevir/ritonavir

    Time frame: up to 14 days

  3. Antiviral activity: Change in HCV RNA levels, measured using Roche COBAS TaqMan HCV Test v2.0 for High Pure System

    Time frame: from baseline to Week 36/48

  4. Antiviral activity: Proportion of patients with unquantifiable/undetectable HCV RNA during the study

    Time frame: approximately 1.5 years

Secondary outcomes

  1. Incidence of viral resistance to danoprevir

    Time frame: approximately 1.5 years

  2. Rapid virological response (RVR): Proportion of patients with undetectable HCV RNA at Week 4

    Time frame: approximately 1.5 years

  3. Complete early virological response (cEVR): Proportion of patients with undetectable HCV RNA at Week 12

    Time frame: approximately 1.5 years

  4. Sustained virological response 12 weeks after end of treatment (SVR-12), defined as unquantifiable HCV RNA 8-20 weeks after the last day of study drug administration

    Time frame: approximately 1.5 years

  5. Sustained virological response 24 weeks after end of treatment (SVR-24), defined as unquantifiable HCV RNA > 20 weeks after the last day of study drug administration

    Time frame: approximately 1.5 years

  6. SVR measured as HCV RNA log10 IU/mL change from baseline to Week 12

    Time frame: approximately 1.5 years

07

Study locations

13 sites
  • Busan, 614-735, Korea, Republic of
  • Seoul, 110-744, Korea, Republic of
  • Seoul, 120-752, Korea, Republic of
  • Seoul, 135-710, Korea, Republic of
  • Chiayi County, 61363, Taiwan
  • Kaohsiung, 807, Taiwan
  • Taichung, 40447, Taiwan
  • Taipei, 100, Taiwan
  • Taoyuan, 333, Taiwan
  • Yunlin County, 640, Taiwan
  • Bangkok, 10330, Thailand
  • Bangkok, 10700, Thailand
  • Chiang Mai, 50200, Thailand
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2012
First posted
Dec 13, 2012
Start
Apr 2013
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01749150
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 13, 2012
Start date
Apr 2013
Primary completion
Feb 2015
Completion
Feb 2015
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Danoprevir · Ritonavir · Peginterferon alfa-2a

Start the discussion